Prognostic value of pretreatment systemic immune‐inflammation index in patients with gastrointestinal cancers

Zhang, Yi; Lin, Shibu; Yang, Xianjin; Wang, Rong; Luo, Lingyan

doi:10.1002/jcp.27373

Cited by 61 publications

(62 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a novel finding for the modern GBM literature, present results convincingly showed that the pretreatment Mediators of Inflammation H-SII was strongly and independently associated with poorer median PFS (6.0 versus 16.6 months; P < 0:001) and OS (11.1 versus 22.9 months; P < 0:001) after the standard RT and TMZ combination. Albeit this is the first report in GBM patients to illustrate significant connections between the SII and survival results, they are harmonious with the outcomes of accessible SII researches and meta-analyses in other cancers [12][13][14][15][16]. In lack of GBM-specific research results, two recent notable studies carefully examined the correlation between the SII levels and glioma grades [18,19], and proposing an increased systemic immune-inflammatory response by increasing glioma grade both reported that the SII was significantly higher in HGG than the LGG.…”

Section: Discussionsupporting

confidence: 67%

“…Another recently emerged novel score that has been tested at many tumor sites, such as the small-cell lung-and non-small-cell lung, hepatocellular, esophageal, biliary system, colorectal and urinary cancers, and acral melanomas for its prognostic value, is the systemic immune-inflammation index (SII): calculated by using the absolute measures of platelets, neutrophils, and lymphocytes obtained from the routine complete blood counts [12]. Besides being confirmed as an efficient prognostic tool in clinical studies and meta-analyses [13][14][15][16], outcomes of a recent esophageal squamous-cell carcinoma study further suggested that SII was superior over both NLR and PLR in prognosis prediction [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

Topkan

Beşen

Özdemir

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Objectives. To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide. Methods. The retrospective data of GBM patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide were analyzed. For each patient, SII was calculated using the platelet, neutrophil, and lymphocyte measures obtained on the first day of treatment: SII=platelets×neutrophils/lymphocytes. The receiver operating characteristic (ROC) curve analysis was utilized for the evaluation of optimal cut-off values for SII those linked with the outcomes. Primary and secondary endpoints constituted the overall (OS) and progression-free survival (PFS) per conveyance SII group. Results. A total of 167 patients were included. The ROC curve analysis identified the optimum SII cut-off at a rounded 565 value that significantly interacted with the PFS and OS and stratified patients into two groups: low-SII (SII<565; n=71) and high-SII (SII≥565; n=96), respectively. Comparative survival analyses exhibited that the high-SII cohort had significantly shorter median PFS (6.0 versus 16.6 months; P<0.001) and OS (11.1 versus 22.9 months; P<0.001) than the low-SII cohort. The relationship between the high-SII and poorer PFS (P<0.001) and OS (P<0.001) further retained its independent significance in multivariate analysis, as well. Conclusions. The outcomes displayed here qualified the pretreatment SII as a novel independent prognostic index for predicting survival outcomes of newly diagnosed GBM patients undergoing postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

Topkan

Beşen

Özdemir

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…This could have been because some variables, such as PLR in the previous research, were considered more significant in the backward stepwise elimination analysis. Similar results were also seen in studies analyzing these markers, together with other tumors (17,18).…”

Section: Discussionsupporting

confidence: 86%

The Impacts of Systemic Immune-Inflammation Index on Clinical Outcomes in Gallbladder Carcinoma

Sun

Jin

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Systemic immune-inflammation index (SII) is considered to be a prognostic marker in several cancers. However, the prognostic value of baseline pre-operative SII in gallbladder carcinoma (GBC) has not been evaluated. This study aimed to determine the prognostic significance of SII and generate a predictive nomogram. Methods: We retrospectively studied 142 GBC patients who underwent surgical resection at the Peking Union Medical College Hospital between 2003 and 2017. SII, neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR) were evaluated for their prognostic values. A multivariate Cox proportional hazards model was used for the recognition of significant factors. Then, the cohort was randomly divided into the training and the validation set. A nomogram was constructed using SII and other selected indicators in the training set. C-index, calibration plots, and decision curve analysis were performed to assess the nomogram's clinical utility in both the training and the validation set. Results: The predictive accuracy of SII (Harrell's concordance index [C-index]: 0.624), NLR (C-index: 0.626), and LMR (C-index: 0.622) was evaluated. The multivariate Cox model showed that SII was a superior independent predictor than NLR and LMR. SII level (≥600) (hazard ratio [HR]: 1.694, 95% confidence interval [CI]: 1.069-2.684, p = 0.024), carbohydrate antigen (CA) 19-9 level (≥37 U/ml) (HR: 2.407, 95% CI: 1.472-3.933, p < 0.001), and TNM stage (p = 0.026) were selected to construct a nomogram for predicting overall survival (OS). The predictive ability of this model was assessed by C-index (0.755 in the training set, 0.754 in the validation set). Good performance was demonstrated by the calibration plot. A high net benefit was proven by decision curve analysis (DCA). Conclusion: SII is an independent prognostic indicator in GBC patients after surgical resection, and the nomogram based on it is a useful tool for predicting OS.

show abstract

“…SII, defined as P (platelet count) x N (neutrophil count)/L (lymphocyte count), combines NLR with platelet count and might have a better predictive power than NLR [26]. As a more objective tumor marker, SII reflects the balance between host inflammation and the state of the immune response [27]. SII has been reported in other studies as a predictor for cancer outcomes, such as small cell lung cancer, GI (gastrointestinal) cancer, and hepatocellular carcinoma [7,8,25].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Huang

Gao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Several studies have reported that the systemic immune-inflammation index (SII) is associated with the prognosis of patients with urologic cancers (UCs). The aim of this study was to systematically evaluate the prognostic value of SII in UC patients. Methods We searched public databases for relevant published studies on the prognostic value of SII in UC patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled to assess the relationships between SII and overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), overall response rate (ORR) and disease control rate (DCR). Results A total of 14 studies with 3074 patients were included. From the pooled results, we found that high SII was associated with worse overall survival (OS) in patients with UC (HR 2.58, 95% CI 1.59–4.21). Patients with high SII values also had poorer PFS (HR 1.92, 95% CI 1.29–2.88) and CSS (HR 2.58, 95% CI 1.36–4.91) as well as lower ORRs (HR 0.40, 95% CI 0.22–0.71) than patients with low SII values. In addition, the subgroup analysis of OS and PFS showed that the prognosis of patients with high SII was worse than that of patients with low SII. Conclusions SII might be a promising noninvasive predictor in patients with UC. However, more samples and multicenter studies are needed to confirm the effectiveness of SII in predicting the prognosis of patients with UC.

show abstract

Prognostic value of pretreatment systemic immune‐inflammation index in patients with gastrointestinal cancers

Cited by 61 publications

References 52 publications

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

The Impacts of Systemic Immune-Inflammation Index on Clinical Outcomes in Gallbladder Carcinoma

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Contact Info

Product

Resources

About